Ascentage Pharma Group International vs Innoviva
AAPG and INVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and INVA compare
Innoviva grew revenue faster over the last twelve months (12.8% versus −41.5% for Ascentage Pharma Group International).
Innoviva scores higher on the StockData Score (14 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | INVA |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.4B |
| Share price | $14.62 | $19.03 |
| Change, 1 year | −55.6% | −14.6% |
| Change, 5 years | – | 11.6% |
| Beta (5Y) | 0.79 | 0.23 |
| Employees | 767 | 159 |
| StockData Score | ||
| Total score | 3 | 14 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 9.7× |
| P/S | – | 3.1× |
| P/B | – | 1.2× |
| EV/EBITDA | – | 6.2× |
| P/FCF | – | 7.5× |
| PEG | – | 0.83 |
| FCF yield | – | 13.3% |
| Fair value | – | $31.77 |
| Margin of safety | – | 40.1% |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 12.8% (better) |
| Revenue growth, 5Y average | – | 4.1% |
| EPS growth, 5Y average | – | 10.3% |
| Profitability | ||
| Gross margin | 91.5% (better) | 74.5% |
| Operating margin | – | 38.8% |
| Net margin | −216% | – |
| FCF margin | −209% | 41.6% (better) |
| Return on equity | −156% | – |
| Return on invested capital | – | 18.0% |
| Financial health | ||
| Debt / equity | 1.50 | 0.23 (better) |
| Net debt / EBITDA | – | −1.90 |
| Interest coverage | – | 8.6× |
| Current ratio | 1.79 | 15.44 (better) |
| Altman Z-score | – | 3.55 |
| Dividends and buybacks | ||
| Buyback yield | – | 5.7% |
| Shareholder yield | – | 5.7% |
| Ownership | ||
| Held by institutions | 0.00% | 104% |
| Held by insiders | 13.0% | 5.4% |
| Short interest, % of float | – | 11.0% |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- INVA stock overview
- INVA income statement
- INVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.